Organic compounds -- part of the class 532-570 series – Organic compounds – Heavy metal containing
Patent
1990-12-05
1992-04-21
Dees, Jose G.
Organic compounds -- part of the class 532-570 series
Organic compounds
Heavy metal containing
556149, 556150, C07F 306
Patent
active
051070065
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to a clathrate compound of a nuclear-substituted salicylic acid salt. The clathrate compound of a nuclear-substituted salicylic acid salt, whose gest molecule is an organic compound, according to the present invention is easily soluble in organic solvents or organic compounds having relatively low polarity and has high stability to light rays and NO.sub.x gases and, therefore, the clathrate compound is suitable for use as an antibiotic, a stabilizer for polymeric compounds or a developer for recording materials.
BACKGROUND ART
Nuclear-substituted salicylic acid and salts thereof have high antibiotic action and have been used as antibiotics (see Japanese Patent Unexamined Publication (hereinafter referred to as "J. P. KOKAI") No. Sho 62-153245). Polyvalent metal salts of a nuclear-substituted salicylic acid have been used as stabilizers for halogen atom-containing polymeric compounds such as polyvinyl chloride (see J. P. KOKAI No. Sho 56-112955). In addition, a polyvalent metal salt of a nuclear-substituted salicylic acid, in particular zinc salt thereof has been used as a developer for recording materials (see J. P. KOKAI Nos. Sho 48-98914, Sho 62-25086 and Sho 63-186729). Moreover, J. P. KOKAI No. 63-293464 which was previously filed by the instant applicant discloses that specific nuclear-substituted salicylic acids and salts thereof are suitable for use as antibiotics, stabilizers for polymeric compounds or developers for recording materials.
DISCLOSURE OF THE INVENTION
The object of the present invention is to improve specific polyvalent metal salts of nuclear-substituted salicylic acids or hydrates thereof in stability to light rays and NO.sub.x gases by converting them into clathrate compounds whose gest molecule is an organic compound and to thus make these compounds more favorable for use as antibiotics, stabilizers for polymeric compounds and developers for recording materials.
According to the present invention, there is provided a clathrate compound of a nuclear-substituted salicylic acid salt which comprises, as a host, crystals of a polyvalent metal salt of a nuclear substituted salicylic acid represented by the following general formula (I) or a hydrate thereof and, as a gest molecule, an organic compound having 1 to 12 carbon atoms: ##STR1## (wherein R.sub.1 and R.sub.2 each represents a tert-butyl group, a tert-amyl group, a tert-octyl group or an .alpha., .alpha.-dimethylbenzyl group). The compound is easily soluble in organic solvents or organic compounds having relatively low polarity and improved in stability to light rays and NO.sub.x gases. Therefore, the compound has enhanced practical value as an antibiotic, a stabilizer for polymeric compounds or a developer for recording materials.
The clathrate compounds are also called inclusion compounds and are crystalline substances which comprise a host crystal constituting the skeletal structure of the crystal and a gest molecule occupying spatial interstices of the host crystal. Therefore, any clathrate compound cannot be formed if there are not present sufficient spatial interstices in the skeletal structure of a crystal. The nuclear-substituted salicylic acid salts rarely form clathrate compounds and the formation of clathrate compounds is a characteristic property peculiar to the polyvalent metal salts of the specific nuclear-substituted salicylic acid represented by the foregoing general formula (I). For instance, a small amount of water is simply coordinated to the polyvalent metal atom in a polyvalent metal salt of 3-(.alpha.,.alpha.-dimethylbenzyl)-6-methylsalicylic acid, 3,5-di-tert-butylsalicylic acid, 3,5 di-tert-amylsalicylic acid or 3,5-di-(.alpha.,.alpha.-dimethylbenzyl)salicylic acid which has a molecular structure similar to that for the compound of Formula (I) and there is no evidence for the formation of any clathrate compound of the foregoing similar compounds. On the other hand, zinc 3,5-di-(.alpha.,.alpha.-dimethylbenzyl)-6-methylsalicylate is obtained in the form of
REFERENCES:
patent: 3983292 (1976-09-01), Saito et al.
patent: 4914219 (1990-04-01), Satomura et al.
Dees Jos,e G.
Nazario Porfirio
Sanko Kaihatsu Kagaku Kenkyusho
LandOfFree
Clathrate compounds of nuclear-substituted salicyclic acid salts does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Clathrate compounds of nuclear-substituted salicyclic acid salts, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Clathrate compounds of nuclear-substituted salicyclic acid salts will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1588008